Zuclopenthixol

Quick links to important sections

Zuclopenthixol

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zuclopenthixol

Quick Facts

Property Description
Active ingredient Zuclopenthixol (dihydrochloride, acetate, decanoate)
Form Tablets (oral), Injection (intramuscular)
Pharmacological class Typical Antipsychotic, Thioxanthene derivative
Common use Psychological stabilization and managing severe distress
Origin Synthetic organic compound

What Type of Medicine is Zuclopenthixol?

Zuclopenthixol is a synthetic organic compound classified as a typical antipsychotic (or first-generation neuroleptic) belonging to the thioxanthene chemical family. This prescription-only medication is a single-ingredient product whose identity is defined by its strong action as a Dopamine Antagonist, which forms the basis for its therapeutic use in managing severe psychiatric conditions. The drug's classification as a thioxanthene derivative relates to its specific chemical structure.


Composition and Physical Forms of Zuclopenthixol

The active ingredient, Zuclopenthixol, is manufactured into three main pharmaceutical preparations to allow for both oral and parenteral intramuscular administration. These preparations involve different salts or esters of the core substance: Zuclopenthixol dihydrochloride is used in oral tablets, while Zuclopenthixol acetate and Zuclopenthixol decanoate are used in injectable solutions. A differentiating factor of this INN is the availability of distinct short- and long-acting injectable forms. The long-acting decanoate form is specifically formulated in an oil base to create a depot, which is crucial for achieving sustained release over several weeks.


General Purpose and Therapeutic Focus

The general purpose of Zuclopenthixol is to help stabilize emotional and mental states by promoting calmer thought processes and behavior. Its core action is to help balance key brain chemicals by reducing the effect of an overactive dopamine system, which is commonly associated with disorganized thinking. By acting as a stabilizing force and reducing neural signal overload, the medication provides the necessary chemical foundation for patients to achieve clearer thinking and emotional stability, supporting the management of severe psychiatric disturbances.

What side effects are possible with Zuclopenthixol?

Possible side effects and safety information

The safety profile of Zuclopenthixol is formally structured by government regulatory agencies, classifying adverse reactions by frequency and affected physiological systems. This summary reflects the high-level safety information documented in official prescribing labels.

Frequency-Classified and System-Specific Effects

Adverse reactions are commonly categorized according to their incidence. Very Common effects include somnolence, akathisia (motor restlessness), and other motor difficulties. Common reactions often involve the central nervous system (e.g., headache, dizziness, tremor) and gastrointestinal system (e.g., dry mouth, constipation), alongside metabolic changes such as weight increased.

Extrapyramidal reactions, such as acute dystonias and parkinsonism, are typically encountered early in treatment or following an adjustment in dose.

Serious Adverse Reactions and Duration-Related Risks

Official documents highlight certain serious adverse reactions, regardless of frequency. The rare but potentially fatal Neuroleptic Malignant Syndrome (NMS) is a documented concern, characterized by hyperpyrexia and muscle rigidity. The risk of Tardive Dyskinesia, an involuntary movement disorder, is associated with prolonged periods of treatment.

Other serious risks include QT prolongation, which affects cardiac repolarization, and the rare occurrence of Venous Thromboembolism (VTE).

Population-Specific Safety Considerations

Specific warnings exist for patient populations as outlined in regulatory labels. Older adults may have an increased risk of extrapyramidal effects, particularly Tardive Dyskinesia. Furthermore, neonates exposed during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. Dosage adjustment is typically recommended for patients with significant hepatic impairment.

Overdose and Emergency Response

Overdose and when to seek help

The following information details the officially documented signs of overdose and required emergency actions, as described in government regulatory documents.

Feature Official Regulatory Statement
Documented overdose presentations Profound somnolence (drowsiness), progression to unconsciousness or coma, convulsions (fits), and pronounced extrapyramidal symptoms (unusual muscle movements or stiffness).
Physiological systems affected Central Nervous System (CNS depression), Cardiovascular system (hypotension, shock, tachycardia, QT prolongation), and Thermoregulatory system (hyperthermia or hypothermia).
When immediate help is required Contact your doctor or nearest hospital emergency department immediately if overdose is suspected. Urgent medical assistance is mandated for symptoms such as passing out, trouble breathing, or signs of severe reaction like Neuroleptic Malignant Syndrome (high fever, muscle stiffness, and consciousness disorder).

Official Overdose Statements

  • Overdose may present with severe CNS depression and is associated with life-threatening cardiac arrhythmias due to documented QT prolongation.
  • Management is limited to symptomatic and supportive treatment and requires continuous monitoring of vital and cardiovascular function, including ECG monitoring.
  • Regulatory documents state explicitly that no specific antidote is known for Zuclopenthixol overdose.

Therapeutic Uses of Zuclopenthixol

What Zuclopenthixol Treats: Main Uses and Benefits

Zuclopenthixol is considered relevant in clinical settings that involve acute or unstable symptom patterns, offering symptomatic relief and stabilization across specific challenging clinical domains. Within these contexts, the medication is generally used for the acute and long-term treatment of schizophrenia and other psychoses, as well as the manic phase of bipolar disorder.

This medication is commonly used during phases when symptoms become more noticeable, including intense agitation, hostility, and potentially aggressive behavior. It helps address symptom clusters that may become intense or disruptive, particularly hallucinations and persistent delusions.

It plays a role in managing the maintenance treatment of chronic psychoses, where the context involves supporting long-term symptom management. This ongoing support assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.

“This treatment supports stability in patients with chronic schizophrenia and may help patients cope more steadily with symptom fluctuations.”


Fact: Supportive Relief

Symptom Domain Therapeutic Context Patient Benefit
Severe Agitation & Hostility Applied in settings marked by temporary physiological imbalance Provides supportive relief, easing distress
Symptom clusters that may become intense or disruptive Acute episodes, supportive symptom management Contributes to improved comfort, steady coping
Chronic Psychosis Maintenance use, long-term support Assists with maintaining functional stability

Regulatory References

  1. NPS MedicineWise

Eligibility and Restrictions for Use

Who Can and Cannot Use Zuclopenthixol?

The population eligibility for Zuclopenthixol is strictly defined by regulatory authorities and includes both absolute prohibitions and required cautions based on patient status.

Populations for Whom Use is Contraindicated

Zuclopenthixol is formally contraindicated and must not be used in patients with:

  • Hypersensitivity to the active substance or any excipients.
  • Circulatory collapse, coma, or a depressed level of consciousness (e.g., due to acute intoxication with alcohol or opiates).
  • Senile confusional states (specifically for the injectable acetate form).

Age-Related and Conditional Use

Population Group Regulatory Status / Limitation
Children and Adolescents (Under 18) Not recommended; safety and efficacy are not established.
Older Adults (Geriatric) Use with caution; typically requires a lower initial dose.
Hepatic Impairment Use with caution; dose reduction should be considered in severe cases.
Pregnancy / Lactation Not recommended unless the expected benefit clearly outweighs the potential risk. Neonates exposed during the third trimester are at risk of extrapyramidal and/or withdrawal symptoms.

Comorbidity-Linked Eligibility Restrictions

Caution is advised for patients with a history of cardiovascular disorders (such as QTc prolongation or significant bradycardia), Parkinson's disease, convulsive disorders (epilepsy), and severe respiratory disease. These restrictions ensure the medicine is only used when the patient meets the established criteria for conditional use as mandated by government labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Zuclopenthixol defines specific interaction patterns, primarily concerning pharmacodynamic risk and metabolic clearance.

Classification Documentation Statement
Contraindicated Combinations The medicine is officially contraindicated with acute intoxication by substances like alcohol, barbiturates, or opiates due to the risk of severe CNS depression. It is also advised to avoid co-administration with other drugs known to significantly increase the QT interval to mitigate cardiac risk.
Metabolic Interactions Zuclopenthixol is partly metabolized by the CYP2D6 enzyme. Concomitant use of CYP2D6 inhibitors may lead to decreased clearance of zuclopenthixol, resulting in increased systemic exposure.

Co-administration with other CNS depressants or general anaesthetics may enhance the sedative effects. The label notes that combining with lithium increases the documented risk of neurotoxicity. Furthermore, the action of guanethidine and similar antihypertensive agents may be officially reduced.

Specific products require procedural constraints: following administration of the Zuclopenthixol acetate injection, all other parenteral antipsychotics must be withheld for 24 hours.

Mechanism of Action

Zuclopenthixol is a thioxanthene derivative that functions primarily as a non-selective antagonist in the central nervous system. Its main biological target is the dopaminergic receptor system, specifically binding to and occupying both the D1 and D2 receptor subtypes. This interaction type competitively blocks the binding and activity of the endogenous neurotransmitter, dopamine.

The drug also demonstrates significant affinity for other receptors, including alpha-1 adrenergic receptors and 5-HT2 serotonergic receptors. By blocking these diverse targets, zuclopenthixol initiates a mechanistic cascade of reduced intracellular signaling downstream of the blocked receptors, which is especially pronounced in the mesolimbic and nigrostriatal pathways. This multi-receptor antagonism results in a broad system-level physiological consequence of modulating overall central nervous system neurotransmission.

Dosage and Administration Information

How to Use Zuclopenthixol

Zuclopenthixol is administered through a dual system, utilizing oral tablets and two distinct intramuscular (IM) injection formulations, which differ in their duration of action. Standard usage protocols involve precise dosing and administration rules based on the formulation.


Official Administration and Dosing

Administration Route Frequency and Regimen Specific Instructions
Oral Tablets (Dihydrochloride) Doses are individually adjusted; maintenance is often 20 – 50 mg/day with a maximum of 150 mg/day. Can be taken with or without food. If a dose is missed, take it as soon as remembered, unless it is less than 6 hours before the next scheduled dose.
IM Injection (Acetate) Used for short-term courses (maximum two weeks), repeated if necessary at intervals of 2 to 3 days. The cumulative dose must not exceed 400 mg. Must be given by deep IM injection into the gluteal region or lateral thigh. This form is not intended for rapid tranquilisation.
IM Injection (Decanoate Depot) Maintenance dose is typically 200 – 500 mg administered every 2 to 4 weeks. The maximum weekly dose is 600 mg. Oral medication is continued in diminishing dosage during the first week after the initial depot injection. Injections over 2 mL must be distributed between two sites.

Population-Specific Rules

Specific dose adjustments are applied for certain patient groups. For older adults, the dosage should be in the lower end of the range, and initial oral doses may be reduced to a quarter or half the normal starting dose. Patients with reduced hepatic function should generally receive half the recommended dosages, with serum-level monitoring advised. While Zuclopenthixol can be given in usual doses in reduced renal function, dosage must be reduced to half in cases of renal failure.

Recent Clinical Evidence

Research Evidence for Chronic Psychoses

Research has evaluated both the oral tablet and the long-acting injectable (depot) forms for use in conditions characterized by periods of heightened symptom activity, such as schizophrenia. Studies primarily took the form of short-term Randomized Controlled Trials (RCTs) comparing the medication to a placebo or to other medications used in similar research. These trials explored how symptoms change over time, applying rating scales to measure areas like delusions and hallucinations. Longitudinal studies with the depot form also monitored symptom patterns over maintenance periods. Studies report patterns observed related to measured changes over time, particularly with the long-acting formulation.


Studies on Acute Symptoms and Key Research Gaps

The injectable acetate formulation was evaluated in research contexts involving rapidly fluctuating symptoms, specifically acute agitation and aggression. These studies were generally small RCTs focusing on effects measured over a short period (hours to days). Research examined outcomes like the speed of tranquilization and the need for supplementary medication. The evidence is limited regarding the speed and depth of the effect, and the sample sizes were modest.

Scientific reviews suggest that certainty remains low across much of the available data, and the evidence quality varies across studies. Long-term effects are not fully established, and follow-up durations were limited. Comparative evidence, which is limited for robust trials against other medications used for similar conditions, remains a major area for ongoing research.

Key Studies & References

  1. Clopixol Acuphase Injection - Summary of Product Characteristics (SmPC) [Acetate]
  2. Psychosis and schizophrenia in adults: prevention and management (NICE Guideline CG178)

Frequently Asked Questions (FAQ)

Common questions about Zuclopenthixol (FAQ)


Q: How quickly does Zuclopenthixol start to have an effect?

The onset of effect depends on the specific formulation used. The short-acting injection is described in official documents as generally starting to work within 2 to 4 hours, with an effect lasting a few days. The effect of the oral and long-acting depot forms is more gradual, as these are used for continuous, ongoing maintenance treatment.


Q: Can Zuclopenthixol be used for long-term treatment?

Yes, one formulation is specifically designed for long-term maintenance. The decanoate (depot) injection form is officially indicated for long-term maintenance treatment to help stabilize conditions over an extended period. This form is typically administered on a scheduled basis every few weeks.


Q: Do you get withdrawal effects if you stop taking Zuclopenthixol?

Official information indicates that suddenly stopping this medication carries a greater risk of experiencing signs of withdrawal. Regulatory guidance describes that if the medication needs to be discontinued, a slow, medically-supervised reduction is generally considered.


Q: Are there specific foods or drinks that should be avoided with Zuclopenthixol?

The oral tablets can generally be taken with or without food. However, official warnings advise that Zuclopenthixol is contraindicated with alcohol due to the risk of severe central nervous system effects. Furthermore, use is advised with caution in patients with diabetes, as the drug may potentially affect glucose control.


Q: Is there a maximum duration for Zuclopenthixol treatment?

A maximum duration is specified for only one of the formulations. The short-acting injection (Acetate) is not intended for long-term use, with treatment typically not exceeding a couple of weeks. The oral and long-acting depot forms, however, are used for maintenance therapy over extended periods.


Q: What happens if a dose of Zuclopenthixol is missed?

The appropriate action for a missed dose depends on the formulation. Regulatory information for oral tablets typically describes instructions for a missed dose, which often involves taking it as soon as it is remembered, unless it is near the time of the next scheduled dose. For the depot injection, patients must strictly follow the injection schedule and specific directions provided by their healthcare team.


Q: Does Zuclopenthixol affect driving or operating machinery?

Yes, official patient information warns that this medication may cause side effects that can affect a person's ability to drive. These possible effects include dizziness, drowsiness, or double vision. Official warnings specify that individuals experiencing these effects should avoid activities like driving or operating heavy machinery.


Q: What specific mental health symptoms is Zuclopenthixol used to control?

Zuclopenthixol is indicated for managing conditions like schizophrenia and other psychoses. Official literature specifies its use, particularly when a condition is accompanied by symptoms such as agitation, aggression, or hostile behavior. Studies also examine its effects on specific psychotic symptoms like delusions and hallucinations.


Q: How long does the main effect of one dose of Zuclopenthixol usually last?

The duration of the main effect varies significantly by formulation. The oral tablet is designed to be taken daily for continuous effect. The short-acting injection typically lasts for 2 to 3 days, while the long-acting depot injection (Decanoate) can be effective for up to 2 to 4 weeks per administration.


Q: Are there any official warnings about stopping Zuclopenthixol abruptly?

Yes, official patient education strongly cautions against suddenly stopping the drug without medical guidance. Doing so is associated with a greater risk of experiencing signs of withdrawal and other reactions. Any decision to stop or change the medication schedule requires consultation with a health care provider.


Q: Can Zuclopenthixol affect fertility?

Official regulatory reviews, primarily based on animal studies, indicate that the drug has been linked to impaired mating performance and reduced conception rates in rats. The clinical significance of these findings for human fertility is currently not clearly established in official patient information.


Q: Can Zuclopenthixol cause issues with blurred vision?

Yes, according to formal documentation on adverse reactions, blurred vision is a reported side effect of Zuclopenthixol. The occurrence of blurred vision or other visual changes is a signal to consult a healthcare professional.


Q: Can Zuclopenthixol affect my blood sugar levels?

Regulatory warnings state that Zuclopenthixol may modify insulin and glucose responses in patients who have diabetes. For this reason, official guidance suggests that monitoring of blood sugar and possible adjustment of antidiabetic therapy may be required during treatment.


Q: Can Zuclopenthixol make depression worse?

Some drug documentation notes that certain antipsychotic medications can cause emotional effects like feeling depressed. However, overall emotional effects can vary, and official regulatory documents do not state a specific worsening of pre-existing depression.


Q: Can Zuclopenthixol cause changes in sexual function?

Changes in sexual function are indirectly addressed in official literature. Due to the drug’s action on brain chemicals, it can lead to a rise in a hormone called prolactin, a condition known as hyperprolactinemia. This increase in prolactin may be linked to effects such as decreased libido and irregular menstrual cycles.


Q: Is Zuclopenthixol available as a generic medicine?

Official drug registration systems list the chemical name, Zuclopenthixol Dihydrochloride, as the generic name. This indicates that it is an established substance for which generic versions exist or may become available, alongside any specific branded product names.

How should Zuclopenthixol be stored and disposed of?

How to Store and Dispose of Zuclopenthixol

Official regulations require specific storage and handling to maintain product integrity and safety.

Storage Requirements

Zuclopenthixol is generally stored below 25 C and must not be frozen, especially the injectable forms. All ampoules must be kept in the outer carton in order to protect from light, and 2 mg tablets must remain in their original container for the same reason. Stability constraints vary by formulation: the unopened Decanoate injection is stable for 36 months, but its in-use stability is limited to 1 day after opening the vial. All formulations must not be used after the expiry date.

️ Disposal and Safety

All medications must be stored out of the sight and reach of children and pets. Any unused medicinal product or waste material, including used syringes, must be disposed of in accordance with local requirements, often by returning items to a pharmacy or official collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Zuclopenthixol found in:

A-Z Index: